• CeraPedics (Lakewood, Colorado), focused on the development of synthetic bone graft products incorporating its small peptide P-15 technology, reported that the results from a pilot study for the treatment of non-union and delayed union fractures have been published in the International Orthopaedics journal. The purpose study assessed the feasibility and clinical outcome of using CeraPedics' P-15 bone graft substitute (P-15 BGS) to treat non-union and delayed union fractures. Full consolidation was achieved in 90% (20 of 22) of the patients treated with the P-15 BGS. The average time for full consolidation was 4.2 months. Histological assessment of the fracture callus in five of the patients confirmed the positive clinical and radiographic results.

• Delcath Systems (Stamford, Connecticut), developer of isolated perfusion technology for region-specific delivery of therapeutic agents, reported that it was featured in the latest edition of the Clinical Journal of Oncology Nursing. The article, “Part II: Nursing Implications of Administering Chemotherapy in Interventional Radiology or the Operating Room,” includes a description of the mechanics used in Delcath's advanced drug delivery system and serves as a training document for oncology nurses.

No Comments